We are live on ! Find out more
AYTU icon

AYTU BioPharma

32 hedge funds and large institutions have $7.45M invested in AYTU BioPharma in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

199% more capital invested

Capital invested by funds: $2.49M → $7.45M (+$4.96M)

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

7.64% more ownership

Funds ownership: 30.42%38.06% (+7.6%)

3% more funds holding

Funds holding: 3132 (+1)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Holders
32
Holders Change
+1
Holders Change %
+3.23%
% of All Funds
0.42%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
5
Reduced
6
Closed
5
Calls
Puts
Net Calls
Net Calls Change

AYTU Hedge Fund Activity: Q2 2025 in Review

32 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q2 2025, worth a combined $7.45M — up 199% from $2.49M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AYTU positions and 5 closed out — a net gain of 2 holders — while 5 added to existing stakes and 6 trimmed.

The largest buyer was AWM Investment Company, opening a new position worth an estimated $963K. The largest seller was Armistice Capital, exiting entirely with an estimated $69.1K sold.

  • 32 institutional investors held AYTU BioPharma (AYTU) as of Q2 2025, up from 31 in Q1 2025.
  • Funds reported $7.45M of AYTU BioPharma stock for Q2 2025, up 199% quarter-over-quarter.
  • 7 funds opened new AYTU BioPharma positions in Q2 2025 and 5 closed out, a net change of +2 holders.
  • The largest AYTU BioPharma buyer in Q2 2025 was AWM Investment Company, an estimated $963K added.
  • The largest AYTU BioPharma seller in Q2 2025 was Armistice Capital, an estimated $69.1K sold.

Based on aggregated 13F filings for Q2 2025.